Product Information
NORTREL 1-35 21 TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.3734 per EA under NDC 00555900942. Its NADAC has been published 628 times since Nov 28, 2013.
FDA first approved this application on Feb 28, 1992. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.035; 1 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555900942
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETHINYL ESTRADIOL; NORETHINDRONEApproval Type
Generic (ANDA)
FDA Application
ANDA072693FDA Approved
2/28/1992
TE Code
AB
On Market Since
6/13/2001
Price Statistics
The NADAC for NORTREL 1-35 21 TABLET has been published 628 times since Nov 28, 2013, and over the history we have for it it has declined 30.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3734 per EA |
|---|---|
| All-time high | $0.7514 (Feb 10, 2021) |
| All-time low | $0.2264 (Jun 21, 2023) |
| 52-week high | $0.4181 |
| 52-week low | $0.3377 |
| Median price | $0.4507 |
| Average price | $0.4663 |
| Largest weekly change | +56.2% (Feb 19, 2020) |
| Weeks tracked | 628 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Norethindrone and Ethinyl Estradiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NORTREL 1-35 21 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NORTREL 1-35 21 TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.3734 per EA (NDC 00555900942), effective Sep 30, 2026.
How has the price of NORTREL 1-35 21 TABLET changed over time?
Over the history we have for it, the NADAC for NORTREL 1-35 21 TABLET has declined 30.2%. It has been tracked across 628 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for NORTREL 1-35 21 TABLET?
Since Nov 28, 2013, the NADAC for NORTREL 1-35 21 TABLET has ranged from a low of $0.2264 (Jun 21, 2023) to a high of $0.7514 (Feb 10, 2021), with a median of $0.4507 per EA.
Are there cheaper alternatives to NORTREL 1-35 21 TABLET?
No other NADAC-published product currently shares the active ingredient and strength of NORTREL 1-35 21 TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NORTREL 1-35 21 TABLET?
NORTREL 1-35 21 TABLET (NDC 00555900942) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.